Rebel
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
lol. Who is "publicly defending illegal actions"? Please share.
lol, You are wrong, Read the complaint.
Who said that? Webslinger: You are wrong. Read the Complaint! The bottom line is that their test was evaluated by the FDA. Out of posts.
Peace out.
Not false! Check the complaint. It's right in there for all the world to see!
We don't know that. I DO know that no federal agency has sent them any sort of "warning letter" or "cease and desist" order that would preclude them from selling their tests.
It is NOT a "false claim" since the FDA evaluated their first attempt and placed it on their "Pre-Emergency Use Authorization" list. That is a fact.
If it were "completely unreliable," the FDA would not have placed it on its "Pre-Emergency Use" list, would it? In fact, at the time, their numbers were actually better than what Abbott's was showing in their EUA test when it made its way to the outside world of hospitals and other providers.
AND I have still not seen anything from the FDA or other government entity that would stop them from using it.
It is NOT a "claim" since the FDA evaluated their first attempt and placed it on their "Pre-Emergency Use Authorization" list.
If their test works, the FDA may still be very interested in their serology Covid-19 antibody test, mostly because people would not have to travel to get tested since the sample is taken by the individual in the privacy and safety of their own home. As far as I know, no such test has been approved yet.
The answer should be quite obvious, i.e., their Covid test is part of the litigation.
That is not true. Everyone wants the truth, and I don't know how "hope" can be "verified." lol.
The truth on that VERY IMPORTANT SUBJECT remains to be seen. That is the bottom line. I am not going to assume anything.
No. "Mark's attorney said..."
It would be a very good thing if it were true. I am well aware that it may not be true. No one on the outside knows for sure.
Really? You must be kidding me!
At least we can sell if we choose to. Peddling koolaid? Where do you see that?
Mark's attorney said in his brief that their updated Covid test was close to 100% in specificity and sensitivity. Is that true and has it been validated? There is still no indication that the FDA sent them any warning letters, and they are not on any do-not-use lists regarding their Covid or allergy tests. So there's that...plus, some of their products have been used in Covid research. If their tests are what they say they are, especially if the samples can be obtained via their in-home finger-stick method, it seems to me that would be very important and lucrative leading the company either to being a buy-out candidate or a means of survival of ARYC.
We shall see.
You don't know how this will end for shareholders, If the company survives, they could become current and successful under new management, especially if their Covid tests are viable and "close to 100% in specificity and sensitivity." If Mark is convicted, there may be funds somewhere to be disgorged and distributed to shareholders. There may be funds available from the two who have already pleaded guilty as well. The worst that could happen is that everything goes bust, which would be sad but somewhat OK for reporting any losses to the IRS to reduce taxable income.
Only time will tell.
He was released on $2 million bail, has been working in the lab, and contrary to the previous post, his release had nothing to do with Covid,
"Please take NOTICE that a Status Conference as to Mark Schena is hereby set for 1/4/2021 01:30 PM in San Jose, Courtroom 4, 5th Floor before Judge Edward J. Davila. (This is a text-only entry generated by the court. There is no document associated with this entry.) (amkS, COURT STAFF) (Filed on 12/8/2020)"
/Pacer/
12/18/20 - Microarray analysis market was estimated to be over US$ 3.7 Billion in 2018. It is anticipated to grow at a CAGR of 7.1% from 2019 to 2030.
The continual growth of the microarray analysis market can be attributed to several factors which have led to wide scale adoption of these devices which are extensively used to study the diverse number of biological processes. Moreover, the growing demand for microarray across the globe is anticipated to further contribute to the substantial growth of the global microarray analysis market between 2019 and 2030. To obtain better insights regarding the market scenario prominent players are increasingly focusing on collaborative initiatives with several institutes and research centers. The National institute for Biomedical Genomics, a publicly funded national institution based in India, has entered into an agreement with Department of Biotechnology, Government of India and Global Alliance for Genomics and Health to share health and genomic related data.
Download PDF to Know the Impact of COVID-19 on “Microarray Analysis Market” at: https://www.marketindustryreports.com/pdf/78
Major Key Players of the Microarray Analysis Market are:
Thermo Fisher Scientific, Agilent Technologies, Molecular Devices, PerkinElmer, Illumina, GE Healthcare, and Bio-Rad Laboratories, Merck KGaA, Arrayit Corporation, Microarrays, Inc. among others.
https://www.medgadget.com/2020/12/microarray-analysis-market-growth-trends-opportunities-and-forecast-to-2030-thermo-fisher-scientific-agilent-technologies-molecular-devices.html
Did I say that? Answer: No.
Good grief.
Yes, of course, that's common knowledge.
The patents have expired. That is what happens after a certain number of years.
It doesn't mean they can't continue to use them.
Here ya go:
Just type in Arrayit Corporation.
https://www.cdc.gov/clia/LabSearch.html
Thank you for that. For some reason making comments or posting facts is interpreted as meaning I don't think that Mark or the company is in any trouble and/or I am a relative encouraging people to invest. Go figure. lol.
lol. First, Arrayit is still operating as a CLIA lab, so calling it "dead" is simply wrong. Second, to back up your statement, please provide links to posts about family members promoting the company to "unsuspecting" investors. I don't see it.
Moratorium may extend until April 30, 2021 for commercial evictions.
Ordinance No. NS-9.289, and Ordinance No. NS-9.292, are designed to prevent. This Ordinance shall expire and shall be repealed as of the earlier of (1) the date that the Governor's Executive Order N- 28-20 (as extended on September 23,2020, by Executive Order N-80-20) suspending any provision of State law that would preempt or otherwise restrict a local government's exercise of police powers to impose substantive limits on commercial evictions under certain conditions (or similar executive order) expires, or (2) to April 30,2021, unless shortened or extended by the Board of Supervisors based on the existence of a local emergency.
https://www.sccgov.org/sites/osh/Documents/County%20Evictions%20Ordinance.pdf
I don't think so. He is still working at the lab.
"tidday tattoos"? huh?
That's the spirit, HYS! "Hope is the last thing ever lost.” —Italian proverb.
Up 116% on over a million shares? Over $1500 invested? (wowie!!) Maybe the DOJ/SEC found a few million or billion dollars in the Cayman Islands that will be disgorged and distributed to the shareholders (after payment of debts and taxes of course).
That must be it. Or something else, like a big surprise or a huge federal contract or something new and good.
You just never know. Nothing wrong with positive thinking or dreaming.
Sellers have to be bonkers selling at these prices, not that I'm not grateful for the .02's and .03's. Whatever games are being played, it's OK with me as my position here continues to grow! VYST never ceases to amaze me.
Well, I do remember her saying that a r/s was not in their plans, but I think that was in 2017 when she was asking shareholders for suggestions on how she could increase shareholder value.
Yes, That fast move was strange and interesting considering the high number of O/S (maybe not so high anymore?)
Wonder what she has going on. Honestly, I never thought we'd hear from her again. For $500K or less they could have bought back 5 billion shares. Would that be too good to be true? Who knows.
At the very least, it's good to know the good doctor is alive and kicking and that something is happening.
Am I dreaming?
SCYNEXIS Announces FDA Acceptance and Priority Review of New Drug Application for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infections 8:00 AM ET 12/7/20 | GlobeNewswire
SCYNEXIS Announces FDA Acceptance and Priority Review of New Drug Application for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infections
-- 6-month Priority Review granted for ibrexafungerp with PDUFA target
action date set for June 1, 2021
-- FDA indicated that it is not currently planning to hold an advisory
committee meeting for the application
-- SCYNEXIS is continuing preparations for a U.S. commercial launch of
ibrexafungerp in 2nd half 2021
JERSEY CITY, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the SCYNEXIS's New Drug Application (NDA) for ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC), also known as vaginal yeast infections. The FDA has granted this application Priority Review, a designation which is granted to applications for potential drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment of serious conditions when compared to standard applications.
Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of June 1, 2021. Additionally, the FDA has communicated that it is not currently planning to hold an advisory committee meeting to discuss the application.
The NDA is supported by positive results from two Phase 3, randomized, double-blind, placebo-controlled, multi-center studies (VANISH-303 and VANISH-306), in which oral ibrexafungerp demonstrated statistically superior efficacy and a favorable tolerability profile in women with VVC.
"The acceptance of this NDA marks a major milestone toward our goal of bringing to market the first new class of antifungals in over 20 years and the first new oral treatment in more than 25 years to the millions of women suffering from vaginal yeast infections," said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. "As the first oral, non-azole treatment for this particularly symptomatic condition, we believe ibrexafungerp has the potential to change the antifungal treatment landscape."
Ibrexafungerp benefits from both Qualified Infectious Disease Product (QIDP) and Fast Track designations granted by the FDA for the treatment of VVC and prevention of recurrent VVC. Under QIDP designation, ibrexafungerp will receive five years of market exclusivity in addition to the five years of exclusivity as a new chemical entity.
Dr. Taglietti added, "We expect to benefit from almost 15 years of market exclusivity, which includes 10 years of regulatory exclusivity as a QIDP product and composition-of-matter patent protection until 2035. We believe this time on the market will allow us to establish ibrexafungerp as a major antifungal franchise and a key treatment option across several indications, which may help the brand attain blockbuster status."
"In VVC alone we believe ibrexafungerp has the potential to achieve significant sales in the U.S., given the large market and the limited treatment options," said Jim Maffezzoli, Vice President of Marketing and Sales. "With over 16 million prescriptions written each year and only one oral product to treat this condition, we believe our novel antifungal treatment has significant potential to address the needs of women and healthcare providers who are not satisfied with the standard of care. Based on ibrexafungerp's unique collection of attributes, including its differentiated mechanism of action, we are confident that, if approved, ibrexafungerp can capture a meaningful percentage of the VVC addressable market with the potential for label expansion in the hospital setting."
About Vulvovaginal Candidiasis (VVC)
VVC, commonly known as a vaginal yeast infection due to Candida, is the second most common cause of vaginitis. Although these infections are frequently caused by Candida albicans, fluconazole-resistant Candida strains, such as Candida glabrata, have been reported to become increasingly more common. VVC can be associated with substantial morbidity, including significant genital discomfort, reduced sexual pleasure, psychological distress and loss of productivity. Typical VVC symptoms include pruritus, vaginal soreness, irritation, excoriation of vaginal mucosa and abnormal vaginal discharge. An estimated 70-75% of women worldwide will have at least one episode of VVC in their lifetime, and 40-50% of them will experience two or more episodes. Approximately 6-8% of women with VVC suffer from recurrent disease, defined as experiencing at least three episodes within a 12-month period.
Current treatments for VVC include several topical azole antifungals (clotrimazole, miconazole, and others) and fluconazole, the only orally-administered antifungal currently approved for the treatment of VVC in the U.S. Fluconazole reported a 55% therapeutic cure rate in its label, which now also includes warnings of potential for fetal harm, illustrating the need for new oral alternatives. The needs of women with moderate-to-severe VVC, recurrent VVC, VVC caused by fluconazole-resistant Candida spp. or VVC during child-bearing age are not fully addressed by oral fluconazole or topical products. In addition, there are no oral alternatives for VVC patients who do not respond to or do not tolerate fluconazole, and there are no FDA-approved products for the prevention of recurrent VVC.
That's not a shareholder class action. It has to do with a food intolerance test processed in their lab - Pinnertest.
That headline is untrue. Period. Haha
The abc7 news link caption is fascinating:
I-TEAM: Owner of Silicon Valley lab faces federal fraud charges, accused of filing more than $69M false COVID-19 test claims
How is that even possible? That statement can't be true.
Judge Davila did sign the last Order:
RELATED CASE ORDER
A Notice of Related Cases has been filed that the following cases are related within the meaning of Crim. L.R. 8-1(b):
5:20-cr-00229-EJD USA v Julie Taguchi
5:20-cr-00425-BLF USA v Mark Schena
5:20-cv-06717-EJD Securities and Exchange Commission v Mark Schena
ORDER
The time for filing a statement to support or oppose the Notice has passed. On the basis of the material submitted to the Court, as the Judge assigned to the earliest filed case, I find that the cases:
( ) ARE NOT RELATED as defined by Crim. L.R. 8-1(b).
( ) ARE RELATED as defined by Crim. L.R. 8-1(b). I find, however, that
reassignment to me of the action(s) currently assigned to another judge is not
warranted.
(X) ARE RELATED as defined by Crim. L.R. 8-1(b). Pursuant to Crim. L.R. 8-1(e), the Clerk of Court is ordered to reassign the later-filed action to the undersigned. Counsel are instructed that all future filings are to bear the initials immediately after the case number. All matters presently scheduled for hearing in the reassigned case(s) are vacated and must be renoticed for hearing before the undersigned.
DATED: 12/1/2020
______________________________________
EDWARD J. DAVILA
United States District Judge
pacer 12/3/20
Did I say that? Answer: No.